ZETACUBE

ZetaCube is an AI-driven biotechnology company specializing in the discovery of novel small molecule therapeutics for "undruggable" targets, with a primary focus on protein-protein interactions (PPIs). The company utilizes its proprietary Z-Platform, which integrates deep learning, molecular dynamics, and structural biology to identify and optimize high-affinity lead compounds. ZetaCube's internal pipeline is currently focused on developing first-in-class candidates for oncology and immunology indications. By combining computational efficiency with rigorous biological validation, the company aims to significantly accelerate the early stages of drug development and improve the success rate of clinical candidates.